TMN 355cyclophilin A inhibitor CAS# 1186372-20-2 |
- Melphalan
Catalog No.:BCC2403
CAS No.:148-82-3
- GRI 977143
Catalog No.:BCC2401
CAS No.:325850-81-5
- Mdivi 1
Catalog No.:BCC2402
CAS No.:338967-87-6
- DAPK Substrate Peptide
Catalog No.:BCC2400
CAS No.:386769-53-5
- Cesium chloride
Catalog No.:BCC2399
CAS No.:7647-17-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1186372-20-2 | SDF | Download SDF |
| PubChem ID | 44249042 | Appearance | Powder |
| Formula | C21H14ClFN2O2 | M.Wt | 380.8 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 40 mM in DMSO | ||
| Chemical Name | 2-chloro-N-(9H-fluoren-9-ylcarbamoyl)-6-fluorobenzamide | ||
| SMILES | C1=CC=C2C(=C1)C(C3=CC=CC=C32)NC(=O)NC(=O)C4=C(C=CC=C4Cl)F | ||
| Standard InChIKey | SFNLLCUAISZNRV-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H14ClFN2O2/c22-16-10-5-11-17(23)18(16)20(26)25-21(27)24-19-14-8-3-1-6-12(14)13-7-2-4-9-15(13)19/h1-11,19H,(H2,24,25,26,27) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent cyclophilin A inhibitor (IC50 = 1.52 nM). Approximately 27 times more potent than cyclosporin A. |
TMN 355 Dilution Calculator
TMN 355 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6261 mL | 13.1303 mL | 26.2605 mL | 52.521 mL | 65.6513 mL |
| 5 mM | 0.5252 mL | 2.6261 mL | 5.2521 mL | 10.5042 mL | 13.1303 mL |
| 10 mM | 0.2626 mL | 1.313 mL | 2.6261 mL | 5.2521 mL | 6.5651 mL |
| 50 mM | 0.0525 mL | 0.2626 mL | 0.5252 mL | 1.0504 mL | 1.313 mL |
| 100 mM | 0.0263 mL | 0.1313 mL | 0.2626 mL | 0.5252 mL | 0.6565 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: 1.52 nM
TMN 355 is a potent cyclophilin A inhibitor, approximately 27 times more potent than cyclosporin A.
In vitro: Remarkably, the PPIase inhibitory activities of derivative TMN 355 has increased up to 1.52 nM, , which are about 27 times more potent than that of CsA. The binding models the most potent inhibitor TMN 355 to CypA was generated by using AUTODOCK 324 and applying a Lamarckian genetic algorithm with a grid space set to be 0.375. Obviously, the binding model of compound 1 to CypA is very similar to that of TMN 355 to CypA, the planar fluorene ring inserts vertically into the hydrophobic gorge area in site A and then forms favorable hydrophobic interactions on account of these two types of appropriate terminal fragments, the acylurea linker of compounds 1 and TMN 355 adopted properly an orientation and interacted well with the saddle site. The interaction models also exhibited that both compounds 1 and TMN 355 form seven hydrogen bonds with residues Arg55, Gln63, and Asn102 in the saddle site. Furthermore, TMN 355 contains a chlorine atom that may impart hydrophobic interaction. The additional interaction was regarded as one of the key factors leading to 20 times potency improvement of TMN 355 compared with compound 1.
In vivo: So far, no study in vivo has been conducted.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1]. Ni S, Yuan Y, Huang J, Mao X, Lv M, Zhu J, Shen X, Pei J, Lai L, Jiang H, Li J. Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach. J Med Chem. 2009 Sep 10;52(17):5295-8. doi: 10.1021/jm9008295.
- Epivogeloside
Catalog No.:BCN6060
CAS No.:118627-52-4
- 4SC-202
Catalog No.:BCC5359
CAS No.:1186222-89-8
- ALW-II-41-27
Catalog No.:BCC1350
CAS No.:1186206-79-0
- NPE-caged-proton
Catalog No.:BCC7698
CAS No.:1186195-63-0
- MTEP hydrochloride
Catalog No.:BCC1780
CAS No.:1186195-60-7
- Tocrifluor T1117
Catalog No.:BCC7401
CAS No.:1186195-59-4
- BU 226 hydrochloride
Catalog No.:BCC6936
CAS No.:1186195-56-1
- Vitexdoin A
Catalog No.:BCN4089
CAS No.:1186021-77-1
- VD3-D6
Catalog No.:BCC4076
CAS No.:118584-54-6
- NVP-BVU972
Catalog No.:BCC3828
CAS No.:1185763-69-2
- Zileuton sodium
Catalog No.:BCC4216
CAS No.:118569-21-4
- Floribundone 1
Catalog No.:BCN4726
CAS No.:118555-84-3
- Evacetrapib (LY2484595)
Catalog No.:BCC2329
CAS No.:1186486-62-3
- 11-Hydroxycodaphniphylline
Catalog No.:BCN6061
CAS No.:1186496-68-3
- H-Cys(Me)-OH
Catalog No.:BCC2908
CAS No.:1187-84-4
- Resminostat hydrochloride
Catalog No.:BCC1888
CAS No.:1187075-34-8
- Cuniloside B
Catalog No.:BCN6062
CAS No.:1187303-40-7
- Trametinib DMSO solvate
Catalog No.:BCC2013
CAS No.:1187431-43-1
- PF 184
Catalog No.:BCC6130
CAS No.:1187460-81-6
- Baricitinib (LY3009104, INCB028050)
Catalog No.:BCC2195
CAS No.:1187594-09-7
- Baricitinib phosphate
Catalog No.:BCC1401
CAS No.:1187595-84-1
- Carabrolactone A
Catalog No.:BCN6063
CAS No.:1187925-30-9
- Carabrolactone B
Catalog No.:BCN6064
CAS No.:1187925-31-0
- Diosbulbin I
Catalog No.:BCN6065
CAS No.:1187951-05-8
Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach.[Pubmed:19691347]
J Med Chem. 2009 Sep 10;52(17):5295-8.
This work describes an integrated approach of de novo drug design, chemical synthesis, and bioassay for quick identification of a series of novel small molecule cyclophilin A (CypA) inhibitors (1-3). The activities of the two most potent CypA inhibitors (3h and 3i) are 2.59 and 1.52 nM, respectively, which are about 16 and 27 times more potent than that of cyclosporin A. This study clearly demonstrates the power of our de novo drug design strategy and the related program LigBuilder 2.0 in drug discovery.
